Last reviewed · How we verify
NCT07400120: PERTg001
Safety Monitoring of VacPertagen Vaccine in Thailand
trial in Pertussis (Whooping Cough) in 5,414 participants. Completed in 21 February 2023.
21 February 2023
Quick facts
| Lead sponsor | BioNet-Asia Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,414 |
| Start date | 16 July 2018 |
| Primary completion | 21 February 2023 |
| Estimated completion | 21 February 2023 |
| Sites | 1 location across Thailand |
Conditions studied
- Pertussis (Whooping Cough) — all drugs for Pertussis (Whooping Cough) →
Sponsor
BioNet-Asia Co., Ltd. — full company profile →
Who can join
Eligibility, any sex, with Pertussis (Whooping Cough). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In compliance with Thailand's conditional approval requirements, this prospective, observational study is designed to actively monitor the safety of VacPertagen vaccine. Healthcare professionals (HCPs) prescribing or administering the vaccine are recruited from hospitals and clinics across central, eastern, southern and northern Thailand. Adverse events following immunization (AEFIs) are reported through standardized questionnaires and modified WHO AEFI forms, enabling systematic evaluation of the vaccine's safety profile in a broader and more heterogeneous population than that assessed in pre-licensure trials. Primary objective: To describe the post-licensure safety profile of VacPertagen in Thailand. Secondary objective: To identify any unexpected safety signals following vaccination with VacPertagen.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07400120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pertussis (Whooping Cough)
Currently open trials in the same condition.
- NCT06827470 — Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis · Phase 1 · recruiting
- NCT06888076 — Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant Women · active not recruiting
- NCT06258057 — Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Preg · active not recruiting
Other BioNet-Asia Co., Ltd. trials
Trials by the same sponsor.
- NCT06798831 — Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Adults · Phase 3 · active not recruiting
- NCT06888076 — Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant Women · active not recruiting
- NCT07213089 — Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy Toddlers · Phase 2, PHASE3 · completed
- NCT07444502 — Safety Monitoring of Boostagen® Vaccine in Thailand · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07400120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioNet-Asia Co., Ltd.
- Last refreshed: 10 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07400120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing